Kidney Research and Clinical Practice

CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management of autosomal domInAnt poLycystic kidney disease (ESSENTIAL): short-term outcomes during the titration period

Hyuk Huh, Yong Soo Kim, Wookyung Chung, Yong Lim Kim, Yaerim Kim, Seungyeup Han, Yeonsoon Jung, Ki Young Na, Kyu Beck Lee, Yun Kyu Oh, Hyeong Cheon Park, Seung Hyeok Han, Tae Hyun Yoo, Yeong Hoon Kim, Soo Wan Kim, Kang Wook Lee, Hayne Cho Park, Sung Gyun Kim, Hyunsuk Kim, Chang Hwa Lee, Kyongtae T. Bae, Kook Hwan Oh, Curie Ahn, Hyun Jin Ryu, Yong Chul Kim

Kidney Res Clin Pract. 2023;42(2):216-228. Published online January 13, 2023
DOI: https://doi.org/10.23876/j.krcp.22.024

Kidney Research and Clinical Practice. 2023;42(2):216-228

Link1

Link2 Link3

Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease

Ioannis Bellos

Therapeutics and Clinical Risk Management. 2021;Volume 17:649-656

Link1 Link2

Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial

Satoru Muto, Tadashi Okada, Moriyoshi Yasuda, Hidetsugu Tsubouchi, Koji Nakajima, Shigeo Horie

Drug, Healthcare and Patient Safety. 2017;Volume 9:93-104

Link1 Link2

Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial [Corrigendum]

Satoru Muto, Tadashi Okada, Moriyoshi Yasuda, Hidetsugu Tsubouchi, Koji Nakajima, Shigeo Horie

Drug, Healthcare and Patient Safety. 2018;Volume 10:67-68

Link1 Link2

MO025: Long-term follow-up of patients with autosomal dominant polycystic kidney disease treated with tolvaptan

Judith Martins Muñoz, Alberto De Lorenzo, Laura Espinel, Blanca Tarragon, Maria Teresa Naya and Alfonso Cubas

Nephrology Dialysis Transplantation. 2022;37(Supplement_3):

Link1

Link2

Short-term changes in micturition patterns with tolvaptan treatment for autosomal dominant polycystic kidney disease

Takashi Hatano, Katsuhisa Endo

Asian Journal of Surgery. 2021;44(10):1332-1333

Link1 Link2

MO031: Long-term safety of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease

Judith Martins Muñoz, Laura Espinel, Alberto De Lorenzo, Blanca Tarragon, Maria Teresa Naya, Alfonso Cubas

Nephrology Dialysis Transplantation. 2022;37(Supplement_3):

Link1

Link2

Commentary on: Tolvaptan in Patients With Autosomal-Dominant Polycystic Kidney Disease

Peter Black, Roger Sutton

Urology. 2013;81(4):705-706

Link1 Link2

Tolvaptan

Reactions Weekly. 2022;1914(1):410-410

Link1

Link2 Link3

Magnetic resonance imaging is effective for evaluating the therapeutic effect of tolvaptan on total kidney volume in patients with autosomal dominant polycystic kidney disease

Shuma Hirashio, Shigehiro Doi, Takao Masaki

Renal Replacement Therapy. 2018;4(1):

Link1

Link2 Link3